Suresh S. Ramalingam, MD, Discusses Adjuvant Therapy for Early NSCLC at 2021 ASCO


During the 2021 ASCO Annual Meeting, Suresh S. Ramalingam, MD, looked forward to how trials regarding adjuvant therapy for early-stage non–small cell lung cancer are poised to change the treatment paradigm in this setting.

CancerNetwork® sat down with Suresh S. Ramalingam, MD, of the Winship Cancer Institute, Atlanta, Georgia, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to talk about a trial involving atezolizumab (Tecentriq) in early-stage non–small cell lung cancer. He said this and other trials involving adjuvant therapy have great potential for clinical impact in the early-disease setting.


I think the adjuvant trial with the atezolizumab in early-stage non–small cell lung cancer is an eagerly anticipated trial. There have been multiple randomized trials that have been completed using immune checkpoint inhibitors in resected non–small cell lung cancer. The IMpower010 [NCT02486718] study is the first one to report out at this year’s meeting, and I believe those results will be discussed and potentially integrated into practice. The notion that we could use immune checkpoint inhibitors in early-stage disease to improve overall outcomes is very exciting, and an important step forward in the management of early-stage lung cancer. We’ve used adjuvant chemotherapy for these patients for nearly 2 decades now, [and] more recently for EGFR-mutated [disease]. Osimertinib [Tagrisso] has gained approval for patients without these targetable mutations. Using immunotherapy would be another novel way to improve their outcomes. I’m very interested in excited about the adjuvant immunotherapy data.


Heather W, Nasser A, Caicun Z, et al. Impower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer. J Clin Oncol. 2021;39(suppl 15):8500. doi:10.1200/JCO.2021.39.15_suppl.8500

Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Expert on NSCLC
Related Content